PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15741653-0	2005	Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors.	ritetronium	33-43	microsomal triglyceride transfer protein	Homo sapiens	79-82
16140902-10	2005	In livers of rats fed the reference diet, ACOL, but not pair feeding, increased protein abundance of the scavenger receptor, class B, type 1, and the LDL receptor, thought to be involved in ACOL-mediated cholesterol lowering.	ritetronium	42-46	low density lipoprotein receptor	Rattus norvegicus	150-162
17020999-0	2006	The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.	ritetronium	109-119	estrogen receptor 1 (alpha)	Mus musculus	59-76
17020999-0	2006	The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.	ritetronium	109-119	estrogen receptor 1 (alpha)	Mus musculus	188-205
15925950-0	2005	Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene.	ritetronium	129-139	estrogen receptor 1 (alpha)	Mus musculus	0-23
15925950-0	2005	Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene.	ritetronium	129-139	estrogen receptor 1 (alpha)	Mus musculus	101-118
15925950-1	2005	OBJECTIVE: The selective estrogen receptor (ER) modulator (SERM) acolbifene (ACOL), a potent and pure antiestrogen in the mammary gland and uterus, exerts beneficial pro-estrogenic actions on energy balance, insulin sensitivity and lipid metabolism.	ritetronium	65-75	estrogen receptor 1 (alpha)	Mus musculus	25-42
15925950-1	2005	OBJECTIVE: The selective estrogen receptor (ER) modulator (SERM) acolbifene (ACOL), a potent and pure antiestrogen in the mammary gland and uterus, exerts beneficial pro-estrogenic actions on energy balance, insulin sensitivity and lipid metabolism.	ritetronium	65-75	estrogen receptor 1 (alpha)	Mus musculus	44-46
15925950-1	2005	OBJECTIVE: The selective estrogen receptor (ER) modulator (SERM) acolbifene (ACOL), a potent and pure antiestrogen in the mammary gland and uterus, exerts beneficial pro-estrogenic actions on energy balance, insulin sensitivity and lipid metabolism.	ritetronium	77-81	estrogen receptor 1 (alpha)	Mus musculus	25-42
15925950-1	2005	OBJECTIVE: The selective estrogen receptor (ER) modulator (SERM) acolbifene (ACOL), a potent and pure antiestrogen in the mammary gland and uterus, exerts beneficial pro-estrogenic actions on energy balance, insulin sensitivity and lipid metabolism.	ritetronium	77-81	estrogen receptor 1 (alpha)	Mus musculus	44-46
15741653-0	2005	Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors.	ritetronium	33-43	scavenger receptor class B member 1	Homo sapiens	97-102
15741653-6	2005	However, in the fasted state, liver concentration of scavenger receptor class B type I (SR-BI) protein, but not mRNA, was 3-fold higher in ACOL-treated than in control animals and correlated with plasma HDL-CHOL levels (r = 0.80, P < 0.002).	ritetronium	139-143	scavenger receptor class B member 1	Homo sapiens	53-86
15741653-6	2005	However, in the fasted state, liver concentration of scavenger receptor class B type I (SR-BI) protein, but not mRNA, was 3-fold higher in ACOL-treated than in control animals and correlated with plasma HDL-CHOL levels (r = 0.80, P < 0.002).	ritetronium	139-143	scavenger receptor class B member 1	Homo sapiens	88-93
12554772-6	2003	Similarly, treatment with the antagonists 4-hydroxytamoxifen and EM-652 abolished all interactions between ERalpha and the SRC RIDs.	ritetronium	65-71	estrogen receptor 1	Homo sapiens	107-114
15720121-10	2005	Incubations of acolbifene with GSH and either tyrosinase or human and rat liver microsomes also produced acolbifene quinone methide-GSH conjugates.	ritetronium	15-25	tyrosinase	Homo sapiens	46-56
15544933-4	2004	SCH 57068 also significantly reduced the increase in bone turnover markers, serum pyridinoline and serum osteocalcin levels, induced by OVX, and increased mechanical bone strength.	ritetronium	0-9	bone gamma-carboxyglutamate protein	Rattus norvegicus	105-116
11850228-2	2001	EM-652 inhibits the AF-1 and AF-2 functions of both ERalpha and beta while the inhibitory action of OH-TAM is limited to AF-2.	ritetronium	0-6	estrogen receptor 1	Homo sapiens	52-59
12566126-0	2003	Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed.	ritetronium	76-85	estrogen receptor 1	Rattus norvegicus	40-57
12566126-12	2003	The estrogen receptor (ER) antagonist ICI 182,780 attenuated E2-induced relaxations but only partially block the effects of EM-652.	ritetronium	124-130	estrogen receptor 1	Rattus norvegicus	23-25
12566126-15	2003	EM-652 attenuated the vasoconstrictor responses induced by adrenergic agonists and endothelin-1.	ritetronium	0-6	endothelin 1	Rattus norvegicus	83-95
31289113-11	2019	Structural features of bazedoxifene and lasofoxifene contributed to AOX1 inhibition, whereas those of acolbifene rendered it considerably less susceptible to AOX1 inhibition.	ritetronium	102-112	aldehyde oxidase 1	Homo sapiens	158-162
9605415-4	1998	EM-652 is 20x more potent than ICI 164384 and Droloxifene while it is 400 times more potent than Toremifene in displacing [3H]E2 from the rat uterine estrogen receptor.	ritetronium	0-6	estrogen receptor 1	Rattus norvegicus	150-167
31289113-3	2019	Therefore, a detailed in vitro and in silico study involving parent drugs and their analogs was conducted to investigate the effect of specific SERMs, particularly acolbifene, bazedoxifene, and lasofoxifene on AOX1 catalytic activity, as assessed by carbazeran 4-oxidation, an AOX1-selective catalytic marker.	ritetronium	164-174	aldehyde oxidase 1	Homo sapiens	210-214
31289113-4	2019	The rank order in the potency (based on IC50 values) of AOX1 inhibition by SERMs was raloxifene > bazedoxifene ~ lasofoxifene > tamoxifen > acolbifene.	ritetronium	149-159	aldehyde oxidase 1	Homo sapiens	56-60
10418981-9	1999	EM-652 has the most potent inhibitory activity on both ER alpha and ER beta compared to any of the other antiestrogens tested.	ritetronium	0-6	estrogen receptor 1	Homo sapiens	55-63
10418981-9	1999	EM-652 has the most potent inhibitory activity on both ER alpha and ER beta compared to any of the other antiestrogens tested.	ritetronium	0-6	estrogen receptor 2	Homo sapiens	68-75
10418981-10	1999	An important aspect of EM-652 is that it inhibits both the AF1 and AF2 functions of both ER alpha and ER beta while the inhibitory action of hydroxytamoxifen is limited to AF2, the ligand-dependent function of the estrogen receptors.	ritetronium	23-29	interferon gamma receptor 2	Homo sapiens	59-62
10418981-10	1999	An important aspect of EM-652 is that it inhibits both the AF1 and AF2 functions of both ER alpha and ER beta while the inhibitory action of hydroxytamoxifen is limited to AF2, the ligand-dependent function of the estrogen receptors.	ritetronium	23-29	estrogen receptor 1	Homo sapiens	89-97
10418981-10	1999	An important aspect of EM-652 is that it inhibits both the AF1 and AF2 functions of both ER alpha and ER beta while the inhibitory action of hydroxytamoxifen is limited to AF2, the ligand-dependent function of the estrogen receptors.	ritetronium	23-29	estrogen receptor 2	Homo sapiens	102-109
10418981-12	1999	EM-652 inhibits Ras-induced transcriptional activity of ER alpha and ER beta and blocks SRC-1-stimulated activity of the two receptors.	ritetronium	0-6	estrogen receptor 1	Homo sapiens	56-64
10418981-12	1999	EM-652 inhibits Ras-induced transcriptional activity of ER alpha and ER beta and blocks SRC-1-stimulated activity of the two receptors.	ritetronium	0-6	estrogen receptor 2	Homo sapiens	69-76
10418981-12	1999	EM-652 inhibits Ras-induced transcriptional activity of ER alpha and ER beta and blocks SRC-1-stimulated activity of the two receptors.	ritetronium	0-6	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	88-93
10418981-13	1999	EM-652 was also found to block the recruitment of SRC-1 at AF1 of ER beta, this ligand-independent activation of AF1 being closely related to phosphorylation of the steroid receptors by protein kinase.	ritetronium	0-6	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	50-55
10418981-13	1999	EM-652 was also found to block the recruitment of SRC-1 at AF1 of ER beta, this ligand-independent activation of AF1 being closely related to phosphorylation of the steroid receptors by protein kinase.	ritetronium	0-6	interferon gamma receptor 2	Homo sapiens	59-62
10418981-13	1999	EM-652 was also found to block the recruitment of SRC-1 at AF1 of ER beta, this ligand-independent activation of AF1 being closely related to phosphorylation of the steroid receptors by protein kinase.	ritetronium	0-6	estrogen receptor 2	Homo sapiens	66-73
10418981-13	1999	EM-652 was also found to block the recruitment of SRC-1 at AF1 of ER beta, this ligand-independent activation of AF1 being closely related to phosphorylation of the steroid receptors by protein kinase.	ritetronium	0-6	interferon gamma receptor 2	Homo sapiens	113-116
9421405-5	1998	EM-652 is also very effective in abrogating E2-stimulated ER alpha and ER beta trans-activation of the pS2 promoter in HeLa cells.	ritetronium	0-6	estrogen receptor 1	Homo sapiens	58-66
9421405-5	1998	EM-652 is also very effective in abrogating E2-stimulated ER alpha and ER beta trans-activation of the pS2 promoter in HeLa cells.	ritetronium	0-6	estrogen receptor 2	Homo sapiens	71-78
9421405-5	1998	EM-652 is also very effective in abrogating E2-stimulated ER alpha and ER beta trans-activation of the pS2 promoter in HeLa cells.	ritetronium	0-6	trefoil factor 1	Homo sapiens	103-106